# The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2017

S.I. 2017/631 · made 6 May 2017

These Regulations amend the Misuse of Drugs Regulations 2001 (S.I. 2001/3998) (“the Regulations”). The Schedule of the Regulations in which a controlled drug is placed affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed and dictates the record keeping, labelling and destruction requirements in relation to that drug.

Made under: Misuse of Drugs Act 1971 (Section 7, Section 10, Section 22, Section 31)

PDFs: Printed copy https://openlegislation.uk/misuse-of-drugs-amendment-england-wales-and-scotland-regulations-2017/pdf/uksi_20170631_en.pdf; UK Explanatory Memorandum https://openlegislation.uk/misuse-of-drugs-amendment-england-wales-and-scotland-regulations-2017/pdf/uksiem_20170631_en.pdf

## Introductory text

Dangerous Drugs, England And Wales
Dangerous Drugs, Scotland
Made 6th May 2017
Coming into force 31st May 2017
To be laid before Parliament 13th June 2017
The Secretary of State makes the following Regulations in exercise of the powers conferred by sections 7, 10, 22 and 31 of the Misuse of Drugs Act 1971.
In accordance with section 31(3) of that Act the Secretary of State has consulted with the Advisory Council on the Misuse of Drugs.

## 1 Citation, commencement and extent

(1) These Regulations may be cited as the Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2017 and come into force on 31st May 2017.
(2) These Regulations extend to England and Wales and Scotland.

## 2 Amendment of the Misuse of Drugs Regulations 2001

The Misuse of Drugs Regulations 2001 are amended as follows.

## 3 Amendment of the Misuse of Drugs Regulations 2001

In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16 , 18, 19, 20, 23, 26 and 27)—
(a) before “Bufotenine” insert—
“Adinazolam (1-(8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine)
N-Benzyl-ethylphenidate
Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)”;
(b) after “Cathinone” insert—
“4’-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)”;
(c) after “Concentrate of poppy-straw” insert—
“Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)
3,4-Dichloroethylphenidate
3,4-Dichloromethylphenidate (3,4-DCMP)
Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;
(d) after “3-Dimethylheptyl-11-hydroxyhexahydrocannabinol” insert—
“Ethylnaphthidate
Ethylphenidate”;
(e) after “Eticyclidine” insert—
“Etizolam”;
(f) after “Etryptamine” insert—
“Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)
4-Fluoroethylphenidate
4-Fluoromethylphenidate
Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;
(g) after “9-(Hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7, 10, 10a-tetrahydrobenzo[c]chromen-1-ol” insert—
“3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one)
Isopropylphenidate (IPP or IPPD)”;
(h) after “Lysergide and other N-alkyl derivatives of lysergamide” insert—
“Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one)”;
(i) after “Methcathinone” insert—
“4-Methylmethylphenidate
Methylmorphenate
Methylnaphthidate (HDMP-28)
Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)
Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2- one)
Nitrazolam (1-Methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)
Propylphenidate”;
(j) after “Psilocin” insert—
“Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)”;
(k) after “3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)” insert—
“3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47,700)”.

## Signature

Sarah Newton
Parliamentary Under Secretary of State
Home Office
6th May 2017

## Explanatory note

(This note is not part of the Regulations)
These Regulations amend the Misuse of Drugs Regulations 2001 (S.I. 2001/3998) (“the Regulations”). The Schedule of the Regulations in which a controlled drug is placed affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed and dictates the record keeping, labelling and destruction requirements in relation to that drug.
Regulation 3 adds a synthetic opioid (known as U-47,700), several methylphenidate related materials and a number of designer benzodiazepines to Schedule 1 to the Regulations. The controlled drugs placed in Schedule 1 to the Regulations are those subject to the tightest controls.
An impact assessment will be published alongside the Explanatory Memorandum on the legislation.gov.uk website.

---
Source: https://www.legislation.gov.uk/uksi/2017/631 (the official version)
Page: https://openlegislation.uk/misuse-of-drugs-amendment-england-wales-and-scotland-regulations-2017
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.